253 related articles for article (PubMed ID: 24401277)
1. Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity.
Bournazos S; Chow SK; Abboud N; Casadevall A; Ravetch JV
J Clin Invest; 2014 Feb; 124(2):725-9. PubMed ID: 24401277
[TBL] [Abstract][Full Text] [Related]
2. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
3. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.
Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K
Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029
[TBL] [Abstract][Full Text] [Related]
4. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo.
DiLillo DJ; Tan GS; Palese P; Ravetch JV
Nat Med; 2014 Feb; 20(2):143-51. PubMed ID: 24412922
[TBL] [Abstract][Full Text] [Related]
5. Divergent Requirement of Fc-Fcγ Receptor Interactions for
Wang S; Ren H; Jiang W; Chen H; Hu H; Chen Z; Zhou P
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331095
[TBL] [Abstract][Full Text] [Related]
6. Differential requirements for FcγR engagement by protective antibodies against Ebola virus.
Bournazos S; DiLillo DJ; Goff AJ; Glass PJ; Ravetch JV
Proc Natl Acad Sci U S A; 2019 Oct; 116(40):20054-20062. PubMed ID: 31484758
[TBL] [Abstract][Full Text] [Related]
7. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
8. Hierarchical and Redundant Roles of Activating FcγRs in Protection against Influenza Disease by M2e-Specific IgG1 and IgG2a Antibodies.
Van den Hoecke S; Ehrhardt K; Kolpe A; El Bakkouri K; Deng L; Grootaert H; Schoonooghe S; Smet A; Bentahir M; Roose K; Schotsaert M; Schepens B; Callewaert N; Nimmerjahn F; Staeheli P; Hengel H; Saelens X
J Virol; 2017 Apr; 91(7):. PubMed ID: 28077656
[TBL] [Abstract][Full Text] [Related]
9. An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin.
Lim NK; Kim JH; Oh MS; Lee S; Kim SY; Kim KS; Kang HJ; Hong HJ; Inn KS
Infect Immun; 2005 Oct; 73(10):6547-51. PubMed ID: 16177329
[TBL] [Abstract][Full Text] [Related]
10. Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity.
Vitale L; Blanset D; Lowy I; O'Neill T; Goldstein J; Little SF; Andrews GP; Dorough G; Taylor RK; Keler T
Infect Immun; 2006 Oct; 74(10):5840-7. PubMed ID: 16988263
[TBL] [Abstract][Full Text] [Related]
11. Maximizing the potency of an anti-TLR4 monoclonal antibody by exploiting proximity to Fcγ receptors.
Loyau J; Malinge P; Daubeuf B; Shang L; Elson G; Kosco-Vilbois M; Fischer N; Rousseau F
MAbs; 2014; 6(6):1621-30. PubMed ID: 25484053
[TBL] [Abstract][Full Text] [Related]
12. Anti-retroviral antibody FcγR-mediated effector functions.
Bournazos S; Ravetch JV
Immunol Rev; 2017 Jan; 275(1):285-295. PubMed ID: 28133801
[TBL] [Abstract][Full Text] [Related]
13. Fcγ Receptor Activation by Human Monoclonal Antibody Aggregates.
Tada M; Aoyama M; Ishii-Watabe A
J Pharm Sci; 2020 Jan; 109(1):576-583. PubMed ID: 31676270
[TBL] [Abstract][Full Text] [Related]
14. Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy.
Cohen Saban N; Yalin A; Landsberger T; Salomon R; Alva A; Feferman T; Amit I; Dahan R
Sci Immunol; 2023 Mar; 8(81):eadd8005. PubMed ID: 36867679
[TBL] [Abstract][Full Text] [Related]
15. Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant.
Mimoto F; Igawa T; Kuramochi T; Katada H; Kadono S; Kamikawa T; Shida-Kawazoe M; Hattori K
MAbs; 2013; 5(2):229-36. PubMed ID: 23406628
[TBL] [Abstract][Full Text] [Related]
16. Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors.
Goulet DR; Zwolak A; Williams JA; Chiu ML; Atkins WM
Proteins; 2020 May; 88(5):689-697. PubMed ID: 31702857
[TBL] [Abstract][Full Text] [Related]
17. Structural analysis of Fc/FcγR complexes: a blueprint for antibody design.
Caaveiro JM; Kiyoshi M; Tsumoto K
Immunol Rev; 2015 Nov; 268(1):201-21. PubMed ID: 26497522
[TBL] [Abstract][Full Text] [Related]
18. An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIa
Kang TH; Lee CH; Delidakis G; Jung J; Richard-Le Goff O; Lee J; Kim JE; Charab W; Bruhns P; Georgiou G
Front Immunol; 2019; 10():562. PubMed ID: 30984171
[TBL] [Abstract][Full Text] [Related]
19. Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.
Liu Z; Gunasekaran K; Wang W; Razinkov V; Sekirov L; Leng E; Sweet H; Foltz I; Howard M; Rousseau AM; Kozlosky C; Fanslow W; Yan W
J Biol Chem; 2014 Feb; 289(6):3571-90. PubMed ID: 24311787
[TBL] [Abstract][Full Text] [Related]
20. Impact of N-glycosylation on Fcγ receptor / IgG interactions: unravelling differences with an enhanced surface plasmon resonance biosensor assay based on coiled-coil interactions.
Cambay F; Henry O; Durocher Y; De Crescenzo G
MAbs; 2019 Apr; 11(3):435-452. PubMed ID: 30822189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
